Prolonged fasting for optimizing myocardial fluorodeoxyglucose suppression
- PMID: 41058139
- DOI: 10.1097/MNM.0000000000002061
Prolonged fasting for optimizing myocardial fluorodeoxyglucose suppression
Abstract
Background: PET with 18F-fluorodeoxyglucose (18F-FDG) is widely used to evaluate inflammatory cardiac disorders such as sarcoidosis and myocarditis. However, physiologic myocardial uptake can obscure pathological uptake and must be suppressed.
Objective: To determine the effectiveness of fasting alone in suppressing physiological myocardial uptake and to establish a practical imaging protocol.
Methods: We retrospectively reviewed patients who underwent whole-body 18F-FDG PET/CT for oncologic indications between January 2019 and December 2020. Patients were categorized by fasting duration: Group A (<12 h), Group B (12-17 h), and Group C (≥18 h). Two independent readers qualitatively graded myocardial FDG uptake, with adequate suppression defined as grade 0 (no uptake) or grade 1 (uptake ≤ liver background). Uptake above liver background (grade 2) was considered inadequate. Interreader agreement was assessed using Cohen's Kappa.
Results: A total of 450 patients were included (150 per group). Adequate myocardial suppression was achieved in 77.3, 66, and 60% of patients in Groups C, B, and A, respectively (P = 0.005). Suppression was not associated with blood glucose, age, or diabetes. However, significant associations were observed with gender (P = 0.024) and BMI (P = 0.006). Interreader agreement was almost perfect (Cohen's Kappa 0.909; 95% CI: 0.868-0.950).
Conclusion: Fasting for ≥18 h is more effective than shorter durations in suppressing physiologic myocardial FDG uptake, enabling evaluation of myocardial inflammation. This simple and feasible protocol is particularly valuable in resource-limited settings. Visual grading demonstrated excellent reproducibility, supporting its role in clinical practice.
Keywords: PET/CT; fasting duration; myocardial fluorodeoxyglucose uptake; physiological uptake suppression.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of F-18-2-fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014; 29:140–145.
-
- Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. Radiographics 2011; 31:1287–1305.
-
- Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42:1551–1555.
-
- Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2017; 24:86–99.
-
- Ding H, Shiau Y, Wang J, Ho S, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F] fluoro-2-deoxy-D-glucose. Nucl Med Commun 2002; 23:961–965.
LinkOut - more resources
Full Text Sources
